

<!--StartFragment-->RESULT 2
AAD56890
ID AAD56890 standard; cDNA; 1279 BP.
XX
AC AAD56890;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human diacylglycerol acyltransferase 2 (DGAT2) cDNA, 112023.
XX
KW Human; diacylglycerol acyltransferase 2; DGAT2; obesity; arrhythmia;
KW coronary artery disease; hypertension; heart failure; tissue typing;
KW aberrant lipogenesis; cardiovascular disorder; atherosclerosis; angina;
KW atrial fibrillation; dilated cardiomyopathy; idiopathic cardiomyopathy;
KW diabetes; chromosome mapping; forensic biology; enzyme; gene; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 42. .1028
FT /*tag= a
FT /product= "Human diacylglycerol acyltransferase 2"
XX
PN WO2003053363-A2.
XX
PD 03-JUL-2003.
XX
PF 19-DEC-2002; 2002WO-US040974.
XX
PR 19-DEC-2001; 2001US-0341947P.
PR 19-SEP-2002; 2002US-0411859P.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Gimeno RE, Wu Z, Kapeller-Libermann R, Hubbard BK;
XX
DR WPI; 2003-559092/52.
DR P-PSDB; AAE37790.
XX
PT New human diacylglycerol acyltransferase 2 (DGAT2) family member
PT polypeptide and nucleic acid molecules, useful for diagnosing and
PT treating obesity, diabetes, atherosclerosis, aberrant lipogenesis or
PT triglyceride synthesis.
XX
PS Claim 1; Page 133-134; 154pp; English.
XX
CC The invention relates to human diacylglycerol acyltransferase 2 (DGAT2)
CC family members and their uses. DGAT2 family member sequences or their
CC modulators are useful for diagnosing and treating a subject with a
CC disorder associated with the aberrant DGAT family member polypeptide
CC activity or nucleic acid expression, such as a disorder associated with
CC obesity, diabetes, aberrant lipogenesis or triglyceride synthesis, or
CC cardiovascular disorder (e.g. atherosclerosis, coronary artery disease,
CC hypertension, heart failure, atrial fibrillation, arrhythmias, dilated
CC cardiomyopathy, idiopathic cardiomyopathy or angina). The invention is
CC also useful in screening assays (e.g. tissue typing, chromosome mapping,
CC or in forensic biology), in predictive medicine (e.g. diagnostic assays,
CC prognostic assays, monitoring clinical trials or pharmacogenetics), or as
CC surrogate markers (e.g. markers of disease states or markers of drug
CC activity). The present sequence is human DGAT2 cDNA
XX

SQ Sequence 1279 BP; 273 A; 352 C; 328 G; 326 T; 0 U; 0 Other;

Query Match 95.9%; Score 1084.8; DB 2; Length 1279;
 Best Local Similarity 98.0%;
 Matches 1109; Conservative 0; Mismatches 22; Indels 1; Gaps 1;

Qy 1 ACTGTTCTGAGATCTTGCCTCCCTCAGGCTCCCGAGAATCATGGCTCATCCAAGCAGC 60
 |||||||
 Db 1 ACTGTTCTGAGATCTTGCCTCCCTCAGGCTCCCGAGAATCATGGCTCATCCAAGCAGC 60

Qy 61 CTAGTCACCCAGAGTCTGATGTTCTGCAGTGGCCTTGAGCTACCTGCCATCTTT 120
 |||||||
 Db 61 CTAGTCACCCAGAGTCTGATGTTCTGCAGTGGCCTTGAGCTACCTGCCATCTTT 120

Qy 121 GGATCTTGCAGCCATTGTTCGTCTACCTGCTGTTACATCCTGTGGCCGCTACCAGTGC 180
 |||||||
 Db 121 GGATCTTGCAGCCATTGTTCGTCTACCTGCTGTTACATCCTGTGGCCGCTACCAGTGC 180

Qy 181 TTTACTTGCCTGGTTGTTCTGGACTGGAAGACCCCAGAGCGAGGTGGCAGGCCTCGG 240
 |||||||
 Db 181 TTTACTTGCCTGGTTGTTCTGGACTGGAAGACCCCAGAGCGAGGTGGCAGGCCTCGG 240

Qy 241 CCTGGGTAAGGAACGGTGTCTGGACCCACATCAGGGACTATTCCCCATTACGATCC 300
 |||||||
 Db 241 CCTGGGTAAGGAACGGTGTCTGGACCCACATCAGGGACTATTCCCCATTACGATCC 300

Qy 301 TGAAGACAAAGGACCTATCACCTGAGCACAACATACCTCATGGGGTTCACCCCCATGGCC 360
 |||||||
 Db 301 TGAAGACAAAGGACCTATCACCTGAGCACAACATACCTCATGGGGTTCACCCCCATGGCC 360

Qy 361 TCCTGACCTTGGCGCCTCTGCAACTCTGCACTGAGGCCACAGGCTCTCGAAGACCT 420
 |||||||
 Db 361 TCCTGACCTTGGCGCCTCTGCAACTCTGCACTGAGGCCACAGGCTCTCGAAGACCT 420

Qy 421 TCCCAGGCATCACTCCTCACTGGCCACGCTGTCTGGTTCTCAAGATCCCCTTGT 480
 |||||||
 Db 421 TCCCAGGCATCACTCCTCACTGGCCACACTGTCTGGTTCTCAAGATCCCCTTGT 480

Qy 481 GGGAGTACCTCATGGCAAAGGTGTGCTCTGTGAGGCCAGCCATCAACTATCTGC 540
 |||||||
 Db 481 GGGAGTACCTCATGGCAAAGGTGTGCTCTGTGAGGCCAGCCATCAACTATCTGC 540

Qy 541 TGAGCCATGGCACTGGCAACCTCGTGGCATTGTAGTGGAGGTGTGGGTGAGGCCCTGC 600
 |||||||
 Db 541 TGAGCCATGGCACTGGCAACCTCGTGGCATTGTAGTGGAGGTGTGGGTGAGGCCCTGC 600

Qy 601 AAAGTGTGCCAACACCACCCCTCATCCTCCAGAAGCGCAAGGGGTCGTGCGCACAG 660
 |||||||
 Db 601 AAAGTGTGCCAACACCACCCCTCATCCTCCAGAAGCGCAAGGGGTCGTGCGCACAG 660

Qy 661 CCCTCCAGCATGGGCTCATCTGGTCCCCACCTTCACTTTGGGAAACTGAGGTGTATG 720
 |||||||
 Db 661 CCCTCCAGCATGGGCTCATCTGGTCCCCACCTTCACTTTGGGAAACTGAGGTGTATG 720

Qy 721 ATCAGGTGCTGTTCCATAAGGATAGCAGGATGTACAAGTCCAGAGCTGCTCCGCCGTA 780
 |||||||
 Db 721 ATCAGGTGCTGTTCCATAAGGATAGCAGGATGTACAAGTCCAGAGCTGCTCCGCCGTA 780

Qy 781 TCTTGGTTCTACTGTTGTCTTATGGACAAAGCTCTGTCAAGGCTCCACTGGGC 840
 |||||||
 Db 781 TCTTGGTTCTACTGTTGTCTTATGGACAAAGCTCTGTCAAGGCTCCACTGGGC 840

Qy 841 TCCTGCCATACTCCAGGCCTATTGTCACTGTGGTTGGGGAGCCTCTGCCACTGCCCAAA 900
|||
Db 841 TCCTGCCATACTCCAGGCCTATTGTCACTGTGGTTGGGGAGCCTCTGCCACTGCCCAAA 900

Qy 901 TTGAAAAGCCAAGCCAGGAGATGGTGGACAAATACCATGCACTTATATGGATGCTCTGC 960
|||||
Db 901 TTGAAAAGCCAAGCCAGGAGATGGTGGACAAATACCATGCACTTATATGGATGCTCTGG 960

Qy 961 ACAAACTGTTGACCAGCATAAGACCCACTATGGCTGCTCAGAGACCCAAAAGCTGTTT 1020
|||||
Db 961 ACAAACTGTTGACCAGCATAAGACCCACTATGGCTGCTCAGAGACCCAAAAGCTGTTT 1020

Qy 1021 TCCTGTGAATGAAGGTACTGCATGCCAGGAGCACAGGAGTGCCTGCC-TTGAAGAAGAG 1079
|||||
Db 1021 TCCTGTGAATGAAGGTACTGCATGCCAGGAGCACAGGAGTGCCTGCCTTGAAAGAAGAA 1080

Qy 1080 ACTCATCTGCCACTAACCAAAGACAGGCAGGAGATGAGGGAGGTATATGTG 1131
|||||
Db 1081 GAATCATCTGGCATAACCAAAGACAGGCAGGAGATGGAGGGAGGTATATGTG 1132

<!--EndFragment-->